Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jinge Zhao

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
The Oncologist|September 6, 2022
Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate CancerSha Zhu, Yuchao Ni, Zilin Wang, et al.
Analytical Chemistry|December 29, 2025
Nanoflower-Shaped Peptide Assemblies Driven by Serrated β-Sheets and Hydrophobic Interactions for High-Affinity MUC1 RecognitionBokai Ma, Jinge Zhao, Shuang Li, et al.
Asian Journal of Surgery|November 14, 2022
The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancerJinge Zhao, Guangxi Sun, Fengnian Zhao, et al.
European Journal of Medical Research|July 20, 2024
Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinomaJunjie Zhao, Xiuyi Pan, Zilin Wang, et al.
The Prostate|August 22, 2019
Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?Tao Wu, Jinge Zhao, Zhenhua Liu, et al.
Communications Medicine|September 26, 2022
Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomesShu Ning, Jinge Zhao, Alan P Lombard, et al.
Clinical Epigenetics|August 8, 2022
Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinomaJunjie Zhao, Jiayu Liang, Yang Yang, et al.
Angewandte Chemie (International Ed. in English)|January 7, 2026
Side-Chain Engineering Guides the Design of β-Sheet Inhibitor to Anchor Protein-Protein Interaction InterfacesLimin Zhang, Minxuan Wang, Bo Wang, et al.
The Prostate|April 17, 2024
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67Fengnian Zhao, Jinge Zhao, Xinyuan Wei, et al.
The Prostate|August 26, 2021
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancerZhipeng Wang, Sha Zhu, Jinge Zhao, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
The Oncologist|September 6, 2022
Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate CancerSha Zhu, Yuchao Ni, Zilin Wang, et al.
Analytical Chemistry|December 29, 2025
Nanoflower-Shaped Peptide Assemblies Driven by Serrated β-Sheets and Hydrophobic Interactions for High-Affinity MUC1 RecognitionBokai Ma, Jinge Zhao, Shuang Li, et al.
Asian Journal of Surgery|November 14, 2022
The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancerJinge Zhao, Guangxi Sun, Fengnian Zhao, et al.
European Journal of Medical Research|July 20, 2024
Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinomaJunjie Zhao, Xiuyi Pan, Zilin Wang, et al.
The Prostate|August 22, 2019
Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?Tao Wu, Jinge Zhao, Zhenhua Liu, et al.
Communications Medicine|September 26, 2022
Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomesShu Ning, Jinge Zhao, Alan P Lombard, et al.
Clinical Epigenetics|August 8, 2022
Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinomaJunjie Zhao, Jiayu Liang, Yang Yang, et al.
Angewandte Chemie (International Ed. in English)|January 7, 2026
Side-Chain Engineering Guides the Design of β-Sheet Inhibitor to Anchor Protein-Protein Interaction InterfacesLimin Zhang, Minxuan Wang, Bo Wang, et al.
The Prostate|April 17, 2024
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67Fengnian Zhao, Jinge Zhao, Xinyuan Wei, et al.
The Prostate|August 26, 2021
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancerZhipeng Wang, Sha Zhu, Jinge Zhao, et al.
Pageof 10